Cite
[Atypical hemolytic uremic syndrome with C3 p.I1157T missense mutation successfully treated with eculizumab].
MLA
Okano, Motohiko, et al. “[Atypical Hemolytic Uremic Syndrome with C3 p.I1157T Missense Mutation Successfully Treated with Eculizumab].” [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology, vol. 59, no. 2, Jan. 2018, pp. 178–81. EBSCOhost, https://doi.org/10.11406/rinketsu.59.178.
APA
Okano, M., Matsumoto, T., Nakamori, Y., Ino, K., Miyazaki, K., Fujieda, A., Sugimoto, Y., Tawara, I., Yamaguchi, M., Ohishi, K., Miwa, H., Masuya, M., Wada, H., & Katayama, N. (2018). [Atypical hemolytic uremic syndrome with C3 p.I1157T missense mutation successfully treated with eculizumab]. [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology, 59(2), 178–181. https://doi.org/10.11406/rinketsu.59.178
Chicago
Okano, Motohiko, Takeshi Matsumoto, Yoshiki Nakamori, Kazuko Ino, Kana Miyazaki, Atsushi Fujieda, Yuka Sugimoto, et al. 2018. “[Atypical Hemolytic Uremic Syndrome with C3 p.I1157T Missense Mutation Successfully Treated with Eculizumab].” [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology 59 (2): 178–81. doi:10.11406/rinketsu.59.178.